The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

Alexion Receives New Japanese Patent

06-Nov-2017 | Source : Alexion Pharmaceuticals Inc. | Visits : 4567
NEW HAVEN, Conn. - Alexion Pharmaceuticals Inc. announced today in a press release that the Japanese Patent Office (JPO) has issued patent No. 6224059, directed to the composition of matter of eculizumab (Soliris®) and pharmaceutical formulations of eculizumab, which will expire in 2027.

“Alexion is pleased that the JPO has granted an additional patent for Soliris, enhancing our global portfolio of intellectual property protection for this novel complement inhibitor,” said Ludwig Hantson, Chief Executive Officer of Alexion. “As we continue to serve patients in Japan and invest in additional research and development for Soliris, we look forward to working with other jurisdictions around the world to further strengthen our patent portfolio.”

As previously announced, the United States Patent and Trademark Office (USPTO) issued three US patents earlier this year directed to the composition of matter of eculizumab, pharmaceutical formulations of eculizumab, and methods of treating paroxysmal nocturnal hemoglobinuria (PNH) with eculizumab. These patents will expire in 2027.

Alexion is pursuing corresponding patent applications for eculizumab in other regions and countries, including Europe. In addition, Alexion is pursuing patent applications for additional indications of Soliris, including for the treatment of anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG).

Related Articles